Prevention of Ototoxicity with Effective Monitoring (POEM) Pharmacokinetic and Auditory Linkages
通过有效监测 (POEM) 药代动力学和听觉联系来预防耳毒性
基本信息
- 批准号:9894986
- 负责人:
- 金额:$ 66.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse eventAffectAminoglycoside AntibioticsAminoglycosidesAntibiotic TherapyAntibioticsAssessment toolAuditoryBacterial InfectionsBehavioralBloodCellular PhoneChildhoodClinicalClinical DataClinical TrialsCommunicationConsumptionCritical IllnessCystic FibrosisDataDiagnosticDiagnostic testsDigit structureDoseDrug ExposureDrug KineticsEarly DiagnosisEffectivenessFollow-Up StudiesFosteringFrequenciesFutureGeneticGenetic DiseasesGenomicsGoalsGuidelinesHealthHealth SciencesHearingHearing TestsHigh-Frequency Hearing LossHumanImprove AccessIndividualIndividual DifferencesInfectionInner Hair CellsInternetKnowledgeLabyrinthLifeLinkLongitudinal observational studyLung infectionsMeasuresMethodsModelingMonitorNoiseOregonOutcomeOutcome StudyPatient Self-ReportPatientsPediatric HospitalsPersonsPharmaceutical PreparationsPharmacodynamicsPharmacogenomicsPharmacotherapyPhenotypePhysiciansPhysiologicalPopulationPredispositionPreventionPrevention trialProtocols documentationPublic HealthPure-Tone AudiometryReportingResearchRiskRisk FactorsSavingsSensorySpeechSynapsesTestingTimeTinnitusTissuesTranslatingUnited States National Institutes of HealthUniversitiesalertnessalternative treatmentaminoglycoside-induced ototoxicityantimicrobialauditory threshold shiftbehavioral responseclinically relevantcohortcystic fibrosis patientsdesigndosageearly awarenesshearing impairmenthearing preservationhigh riskimprovedinnovationnephrotoxicityneural hearing lossnovelotoacoustic emissionototoxicitypermanent hearing losspreservationpreventprevent hearing lossprogramsprospectiverelating to nervous systemresponseside effecttooluptakeyoung adult
项目摘要
PROJECT SUMMARY/ABSTRACT
Patients treated with life-saving aminoglycoside (AG) antibiotics may experience adverse side effects of
ototoxicity – permanent hearing loss and degraded speech communication. There are critical gaps in our
understanding of individual susceptibility for ototoxicity, and access to effective tests that identify those at
higher risk. The objective of this proposal is to determine the effect of AG antibiotics on auditory function in
relation to individual measures of drug exposure in patients with cystic fibrosis. Our long-term goal is to design
improved auditory monitoring protocols to prevent hearing deficits due to ototoxicity in patients taking AG
antibiotics. This project will evaluate new methods to detect onset of ototoxicity using extended high frequency
(EHF) tests of inner ear function – otoacoustic emissions (OAEs) and digits in noise (DIN), in relation to
individualized pharmacokinetic/dynamic (PK/PD) measures of drug exposure. Cystic fibrosis (CF) is the most
common life-threatening genetic disease and causes persistent lung infections in childhood that are frequently
treated with AG antibiotics, thus is an important population to target for prevention of ototoxicity. This
longitudinal observational study will include CF patients treated with AG antibiotic treatments, and control
persons not treated with AGs, half of whom also have CF. Our hypothesis is that these newly developed
auditory tests can detect ototoxicity early and are related to the PK/PD models. Further, we hypothesize that
PK/PD models can predict risk for ototoxicity. Currently, most patients at risk are not monitored for ototoxic
hearing loss, primarily due to lack of availability and awareness of early detection methods, as well as
treatment alternatives that can preserve hearing. Tests that can be automated or delivered remotely via the
internet or through smartphones could fundamentally improve access to ototoxicity monitoring. The proposed
longitudinal observational design is impactful because it will provide highly translatable auditory data in relation
to advanced measures of drug exposure. The clinically relevant aims will: (1) Assess relationships over time
between cumulative doses of AGs, shifts in EHF pure tone and DIN tests, and self-reported hearing difficulty
and tinnitus; (2) Compare OAE tests to hearing loss shifts and determine which OAE test is more accurate to
detect presence of ototoxicity; (3) Develop a clinical PK/PD tool to predict AG ototoxicity (change in
audiometry, DIN or OAEs) in relation to AG tissue accumulation in CF patients. The expected outcomes will
have important positive impacts because they will provide a better understanding of ototoxicity mechanisms,
timing and risk factors that can be translated into improved monitoring. Future genomic studies and clinical
trials to protect the inner ear would be facilitated by this expanded knowledge and by availability of improved
diagnostic and monitoring tools.
项目总结/摘要
使用挽救生命的氨基糖苷类(AG)抗生素治疗的患者可能会出现以下不良副作用:
耳毒性-永久性听力丧失和言语交流能力下降。在我们的研究中,
了解个体对耳毒性的敏感性,并获得有效的测试,以确定那些在
更高的风险。本建议的目的是确定AG抗生素对听力功能的影响,
与囊性纤维化患者药物暴露的个体测量相关。我们的长期目标是设计
改善听觉监测方案,以预防使用AG的患者因耳毒性导致的听力缺陷
抗生素本项目将评估新的方法来检测使用扩展的高频率耳毒性发作
(EHF)内耳功能测试-耳声发射(OAE)和噪声数字(DIN),与
药物暴露的个体化药代动力学/动态(PK/PD)测量。囊性纤维化(CF)是最常见的
常见的危及生命的遗传性疾病,并导致儿童期持续性肺部感染,
用AG抗生素治疗,因此是预防耳毒性的重要目标人群。这
纵向观察性研究将包括接受AG抗生素治疗的CF患者和对照组
未接受AG治疗的人,其中一半也患有CF。我们的假设是,这些新开发的
听觉测试可以早期检测耳毒性,并且与PK/PD模型相关。此外,我们假设,
PK/PD模型可以预测耳毒性的风险。目前,大多数处于风险中的患者没有监测耳毒性
听力损失,主要是由于缺乏早期检测方法的可用性和意识,以及
可以保留听力的治疗方法。可以自动化或通过远程交付的测试
互联网或通过智能手机可以从根本上改善耳毒性监测。拟议
纵向观察设计是有影响力的,因为它将提供高度可翻译的听觉数据,
先进的药物暴露测量方法临床相关的目标将:(1)评估随时间的关系
AGs累积剂量、EHF纯音和DIN测试的变化以及自我报告的听力困难之间的关系
和耳鸣;(2)将OAE测试与听力损失变化进行比较,并确定哪种OAE测试更准确,
检测耳毒性的存在;(3)开发临床PK/PD工具以预测AG耳毒性(
听力测定、DIN或OAE)与CF患者中AG组织蓄积相关。预期成果将
具有重要的积极影响,因为它们将提供对耳毒性机制的更好理解,
可以转化为更好的监测的时间和风险因素。未来的基因组研究和临床
保护内耳的试验将通过这种扩展的知识和改进的
诊断和监测工具。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Martin Patrick Feeney其他文献
Martin Patrick Feeney的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Martin Patrick Feeney', 18)}}的其他基金
Prevention of Ototoxicity with Effective Monitoring (POEM) Pharmacokinetic and Auditory Linkages
通过有效监测 (POEM) 药代动力学和听觉联系来预防耳毒性
- 批准号:
10468819 - 财政年份:2020
- 资助金额:
$ 66.3万 - 项目类别:
Prevention of Ototoxicity with Effective Monitoring (POEM) Pharmacokinetic and Auditory Linkages
通过有效监测 (POEM) 药代动力学和听觉联系来预防耳毒性
- 批准号:
10684143 - 财政年份:2020
- 资助金额:
$ 66.3万 - 项目类别:
Prevention of Ototoxicity with Effective Monitoring (POEM) Pharmacokinetic and Auditory Linkages
通过有效监测 (POEM) 药代动力学和听觉联系来预防耳毒性
- 批准号:
10237876 - 财政年份:2020
- 资助金额:
$ 66.3万 - 项目类别:
Tympanometric laser Doppler vibrometry measurements of middle ear function
鼓室导抗激光多普勒振动测量中耳功能
- 批准号:
9922131 - 财政年份:2019
- 资助金额:
$ 66.3万 - 项目类别:
Tympanometric laser Doppler vibrometry measurements of middle ear function
鼓室导抗激光多普勒振动测量中耳功能
- 批准号:
10424361 - 财政年份:2019
- 资助金额:
$ 66.3万 - 项目类别:
Tympanometric laser Doppler vibrometry measurements of middle ear function
鼓室导抗激光多普勒振动测量中耳功能
- 批准号:
10610345 - 财政年份:2019
- 资助金额:
$ 66.3万 - 项目类别:
National Center for Rehabilitative Auditory Research
国家听力康复研究中心
- 批准号:
10043832 - 财政年份:2017
- 资助金额:
$ 66.3万 - 项目类别:
National Center for Rehabilitative Auditory Research
国家听力康复研究中心
- 批准号:
9468270 - 财政年份:2017
- 资助金额:
$ 66.3万 - 项目类别:
National Center for Rehabilitative Auditory Research
国家听力康复研究中心
- 批准号:
10268979 - 财政年份:2017
- 资助金额:
$ 66.3万 - 项目类别:
Comprehensive Wide Bandwidth Test Battery of Auditory Function in Veterans
退伍军人听觉功能的综合宽带测试电池
- 批准号:
9052737 - 财政年份:2014
- 资助金额:
$ 66.3万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 66.3万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 66.3万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 66.3万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 66.3万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 66.3万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 66.3万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 66.3万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 66.3万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 66.3万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 66.3万 - 项目类别: